Login to Your Account



Onyx, Bayer Enjoy 'Upside Surprise' on Regorafenib

By Marie Powers
Staff Writer

Thursday, October 27, 2011

Ahead of schedule, on Wednesday Onyx Pharmaceuticals Inc. and partner Bayer HealthCare Pharmaceuticals reported positive Phase III data for the VEGF-multikinase inhibitor regorafenib (BAY 73-4506) in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard treatment.

While keeping details under wraps, the companies said the trial met its primary endpoint of statistically significant improvement in overall survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription